TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06485128

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample
Description: For both routine cardiovascular health biomarkers as well as genetic markers (DNA, mRNA, miRNA).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Skin biopsy
Description: Spatial proteomics and transcriptomics for endothelial function.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Skin biopsy
Description: Spatial proteomics and transcriptomics for endothelial function.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Skin biopsy
Description: Spatial proteomics and transcriptomics for endothelial function.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Skin biopsy
Description: Spatial proteomics and transcriptomics for endothelial function.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Skin biopsy
Description: Spatial proteomics and transcriptomics for endothelial function.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neuropsychological examination
Description: Moca, Stroop color word test, concept shifting test, COWAT, (R)AVLT, Beck depression inventory, GDS

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neuropsychological examination
Description: Moca, Stroop color word test, concept shifting test, COWAT, (R)AVLT, Beck depression inventory, GDS

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neuropsychological examination
Description: Moca, Stroop color word test, concept shifting test, COWAT, (R)AVLT, Beck depression inventory, GDS

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neuropsychological examination
Description: Moca, Stroop color word test, concept shifting test, COWAT, (R)AVLT, Beck depression inventory, GDS

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neuropsychological examination
Description: Moca, Stroop color word test, concept shifting test, COWAT, (R)AVLT, Beck depression inventory, GDS
Study: NCT04589091

Intervention type: OTHER
Intervention: Refractive surgery
Description: Refractive surgery for correction of error of refraction

Intervention type: OTHER
Intervention: Refractive surgery
Description: Refractive surgery for correction of error of refraction
Study: NCT05911594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin group
Description: Patients in this group will receive medical treatment (Solifenacin 5 mg once or twice daily) without any second line of treatment
Study: NCT05342285

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow mediated dilation
Description: flow mediated dilation in brachial artery

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow mediated dilation
Description: flow mediated dilation in brachial artery

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow mediated dilation
Description: flow mediated dilation in brachial artery
Study: NCT06188091

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Physiotherapeutic instructions to patients to do active exercise to improve the mobility of knee joint post-surgical

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Physiotherapeutic instructions to patients to do active exercise to improve the mobility of knee joint post-surgical
Study: NCT06149130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: adebrelimab:1200mg intravenously, Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalpiciclib
Description: dalpiciclib:150mg once a day for 3 weeks and stop for 1 week. Q4W.
Study: NCT03598374

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inositol + Folic acid
Description: Daily oral supplementation of for 6 months or until pregnancy conception:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: Daily oral supplementation of for 6 months:~Folic acid: 400 mcg

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Regular intercourses
Description: Couples are required to have regular intercourses with the aim to achieve a spontaneous conception.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular intercourses
Description: Couples are required to have regular intercourses with the aim to achieve a spontaneous conception.
Study: NCT03657394

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical cord milking
Description: At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 1--15 seconds.
Study: NCT06132698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab, pemetrexed
Description: Drug 1: Tislelizumab 50 mg; Drug 2: pemetrexed 20mg. intrathecal injection therapy
Study: NCT05757245

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GMCN-508A Drug Product
Description: Transplant of autologous hematopoietic stem and progenitor cells transduced with GMCN-508A lentiviral vector.
Study: NCT05911594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation group
Description: Patients in this group will receive Percutaneous tibial nerve stimulation after failure of medical therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradetrusor BOTOX group
Description: Patients in this group will receive Intradetrusor BOTOX after failure of medical
Study: NCT05551780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoundBite Crossing System
Description: Use of the SoundBite Crossing System to cross calcified chronic total occlusions
Study: NCT05911594

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation group
Description: Patients in this group will receive Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation after failure of medical
Study: NCT06068582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strenghtening the brain
Description: Lifestyle intervention containing physical exercise, lifestyle coaching, and cognitive training. The programme contains weekly 30 minutes 1-on-1 fitness and lifestyle coaching with two moments of exercise at home for 20 minutes. Online computerized cognitive training will be done for 60 minutes per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengthening the mind
Description: Work-focused intervention combining the capability approach and the participatory approach. Together with a work-coach who has been diagnosed with MS themselves, participants will assess important work values, discover challenges participants are facing, think of solutions for these challenges, develop a plan of action and implement these solutions.
Study: NCT06259799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Water Bottle
Description: Participants in the intervention group will receive a bottle which measures participant fluid consumption. The bottle will be set to recommend 2.5L for male participants and 2.0L for female participants, consistent with fluid intake recommendations from the European Food Safety Authority for each sex. Participants will be prompted by the bottle (bottle will light up) when they are behind on fluid intake recommendations. Participants will use a validated urine color chart, 9 point Likert scale for thirst, and measure nude body mass on their own each morning. Participants will be informed that higher values for nude body mass and thirst, and lower values for nude body mass each morning may indicate they are less hydrated day-to-day.
Study: NCT05983562

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: D-β-hydroxybutyric acid with R-1,3-butanediol
Description: Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inert placebo
Description: Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively
Study: NCT05220683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital marking system
Description: Verion or Callisto, digital marking system
Study: NCT05357898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SQZ-eAPC-HPV
Description: Enhanced antigen presenting cells (eAPC) cell therapy; therapeutic vaccine engineered from autologous peripheral blood mononuclear cells (PBMCs) by incorporating 5 mRNAs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SQZ-eAPC-HPV
Description: Enhanced antigen presenting cells (eAPC) cell therapy; therapeutic vaccine engineered from autologous peripheral blood mononuclear cells (PBMCs) by incorporating 5 mRNAs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SQZ-eAPC-HPV
Description: Enhanced antigen presenting cells (eAPC) cell therapy; therapeutic vaccine engineered from autologous peripheral blood mononuclear cells (PBMCs) by incorporating 5 mRNAs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: programmed cell death 1 (PD-1) blocking antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: programmed cell death 1 (PD-1) blocking antibody
Study: NCT06403761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly semaglutide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly semaglutide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive once-weekly cagrilintide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive once-weekly cagrilintide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo semaglutide
Description: Participants will receive once-weekly placebo matched to semaglutide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo semaglutide
Description: Participants will receive once-weekly placebo matched to semaglutide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo semaglutide
Description: Participants will receive once-weekly placebo matched to semaglutide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo cagrilintide
Description: Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo cagrilintide
Description: Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cagrilintide
Description: Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.
Study: NCT06406491

Intervention type: DEVICE
Intervention: active microprocessor-controlled knee
Description: Active microprocessor-controlled knees are motorized prosthesis, actively supporting the users while walking, getting up, and climbing stairs.
Study: NCT06349538

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical examination, blood draw, cerebral MRI, sonography, tremor analysis, OCT, olfactory mucosa swab.
Description: see previous descriptions
Study: NCT05812781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX2735
Description: Dose A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX2735
Description: Dose B
Study: NCT05207709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib + Letrozole OR Fulvestrant
Description: Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib + Letrozole OR Fulvestrant
Description: Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel +/- Tislelizumab
Description: Patients in this arm could receive as the first line of therapy
Study: NCT04649411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric citrate
Description: oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: administered per the approved label and at the Investigator's discretion
Study: NCT05868564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atherectomy+Drug-coated balloon
Description: Patients in experimental group will undergo endovascular treatment for femoropopliteal lesions. The lesion will be treated by atherectomy+drug-coated balloon in the experimental group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-coated balloon
Description: drug-coated balloon only in the active comparator group.
Study: NCT05087524

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BinaxNOW Ag Card
Description: A nasal swab specimen is collected from the participant, 6 drops of extraction reagent from a dropper bottle are added to the top hole of the swab well. The participant sample is inserted into the test card through the bottom hole of the swab well, and firmly pushed upwards until the swab tip is visible through the top hole. The swab is rotated 3 times clockwise and the card is closed, bringing the extracted sample into contact with the test strip. Test results are interpreted visually at 15 minutes based on the presence or absence of visually detectable pink/purple colored lines.
Study: NCT06078956

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Measuring of analytes
Description: Method Comparison Study for pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb and FHHb in whole blood in adult population.

Intervention type: DEVICE
Group type: OTHER
Intervention: Measuring of analytes
Description: Method Comparison Study for pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb and FHHb in whole blood in adult population.
Study: NCT06334445

Intervention type: BEHAVIORAL
Intervention: Control group
Description: Wearables/sensors and ePsycHeart App

Intervention type: BEHAVIORAL
Intervention: Intervention group
Description: Wearables/sensors and ePsycHeart App and eHealtHeart
Study: NCT06405009

Intervention type: OTHER
Intervention: Without any intervention, we only divided gastric cancer patients into two groups based on postoperative pathology, and analyzed their basic characteristics and risk factors
Description: Without any intervention, we only divided gastric cancer patients into two groups based on postoperative pathology, and analyzed their basic characteristics and risk factors

Intervention type: OTHER
Intervention: Without any intervention, we only divided gastric cancer patients into two groups based on postoperative pathology, and analyzed their basic characteristics and risk factors
Description: Without any intervention, we only divided gastric cancer patients into two groups based on postoperative pathology, and analyzed their basic characteristics and risk factors
Study: NCT05445310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib 80mg/d
Study: NCT05731674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Random selection of excercises
Description: Participants in the intervention group will train using a random selection of excercises and complete the profiency-based traning program.
Study: NCT05235321

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard GAT
Description: Standard Goldmann Applanation Tonometry (GAT): this is the standard method for IOP measurement in clinical practice

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed force GAT
Description: An investigational device similar to standard GAT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upright applanating prototype
Description: An investigational device, prism used in standard and fixed-force GAT is attached to a portable device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supine Applanating Prototype
Description: An investigational device, prism used in standard and fixed-force GAT is attached to a portable device performed in the supine position
Study: NCT04816838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: \* Osimertinib 80mg once a day(QD) oral(PO)~Neoadjuvant Period -If there is no disease progression or unacceptable toxicity, treatment is performed for 2cycles at 1 cycle (28 days) interval~Adjuvant Period~- If there is no disease progression of unacceptable toxicity, treatment fis performed for 3years at intervals of 1cycle(28days)
Study: NCT06279910

Intervention type: DRUG
Intervention: Calcifediol
Description: Calcifediol added as a treatment to the rest of the prescribed drugs of the protocol
Study: NCT05326841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: cholecalciferol tablet, the dose is 5000 international unit /day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: cholecalciferol tablet, the dose is 5000 international unit /day for 12 weeks
Study: NCT05404386

Intervention type: OTHER
Group type: OTHER
Intervention: Training booklet prepared by the researchers on healthy lifestyle behaviors, bladder training, and Kegel exercises related to urinary incontinence.
Description: After the participants enrolled in the study, a training booklet prepared by the researchers on healthy lifestyle behaviors, bladder training, and Kegel exercises related to urinary incontinence will be given to the participants.

Intervention type: OTHER
Group type: OTHER
Intervention: 3 months follow-up
Description: Follow-ups will be made 3 times in total, on the basis of pre-test (baseline), intermediate follow-up test (6th week), and post-test (12th week).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 months follow-up
Description: Follow-ups will be made 3 times in total, on the basis of pre-test (baseline), intermediate follow-up test (6th week), and post-test (12th week).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application which named as My Fighting with Incontinence
Description: The mobile application My Fighting with Incontinence aims to reduce incontinence symptoms of women with UI, ensure compliance with Kegel exercises, increase health belief and quality of life regarding UI and kegel exercises, and also allow researchers to be included in the awareness and management process.
Study: NCT05622422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER-BKP
Description: The intervention aims to activate patients' inherent resources and by this, facilitate empowerment, patient activation, and self-care management of their chronic disease. The participants will include people 18 years and older that have been diagnosed with a chronic disease. This pilot study will use a pre-post design. Some of the data will be collected initially at the first session and then again at the seventh session. The intervention will be provided in seven sessions the first three will be face-to-face at a community center and then the last four sessions will be through video conferencing and will be facilitated by three researchers. The participants will be invited to a focus group interview in week nine in order to collect quantitative data. Once the sessions are finished both qualitative and quantitative data will be collected and then analyzed.
Study: NCT05707962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: All babies with moderate or severe Hypoxic Ischemic Encephalopathy fulfilling the inclusion criteria will be randomized to receive either the standard treatment (oxygen and fluid therapy along with anticonvulsants if required) plus 3.0 ml/kg of 10% dextrose water given over 30 minutes, three dose given 24 hours apart or to receive standard treatment PLUS three doses of Magnesium Sulphate infusion given over 30 minutes at 250 mg/kg per dose given 24 hours apart. The volume of infusion shall be adjusted with 10% dextrose water to make it~up to 3.0 ml. The resulting reconstituted solution for intravenous infusion shall be 8.3% Magnesium Sulphate delivered over 30 minutes at a rate of 0.1 ml/kg/minute i.e. 8.3 mg/kg/minute. The treatment should be started as soon after birth as possible and not later than 24 hours of life. The babies who meet the exclusion criteria will not be continued into the study.
Study: NCT03509545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF Patients: ER Torsemide 40 mg
Description: ER Torsemide 40mg given once daily to CHF patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF Patients: Furosemide 40 mg
Description: Stable CHF patients taking twice-daily 40 mg Furosemide
Study: NCT04298177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation using the QDOT® catheter
Description: Atrial fibrillation ablation will be performed using the QDOT® catheter. The ablation mode will be selected according to the MDCT-derived LAWT information.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard atrial fibrillation ablation
Description: Atrial fibrillation ablation will be performed using the SmartTouch® catheter. The ablation parameters will be adjusted according to the settings previously described in the CLOSE study.
Study: NCT04891744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100mg/d, Po. on day1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg/d Po. on day 1, 2,8,9,15,16,22,23
Study: NCT05430698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1antibody plus GEMOX
Description: 1. PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~2. GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1，intravenous infusion.~3. Three weeks is a course of treatment,a total of 6-8 courses.
Study: NCT05478395

Intervention type: OTHER
Intervention: Questionnaires set
Description: Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
Study: NCT05528744

Intervention type: OTHER
Intervention: Observational Study
Description: No intervention. This is an observational study

Intervention type: OTHER
Intervention: Sample collection only
Description: Collection of blood and/or skin samples.